comparemela.com

Catherine Leveau News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sensorion Receives Positive Opinion for Orphan Drug Designation for OTOF-GT for the Treatment of Oto

MONTPELLIER, France (BUSINESS WIRE) Regulatory News:Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the European Medicine.

France generalInstitut pasteurCatherine leveauMatthew cole jessica hodgsonCommittee for orphan medicinal productsRegulatory affairsEuropean medicines agencyEuropean commissionHealth technology assessments htasInternational media relationsConsilium strategic communicationsRegulatory newsOrphan medicinal productsOrphan drug designationQuality assurance directorClinical trial application

Sensorion to participate in the Inner Ear Biology Workshop in September 2022

Regulatory News: Sensorion (FR0012596468 ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent

France generalChristophe tran van baInstitut pasteurMary jane elliott jessica hodgsonCatherine leveauStrategic communicationsInternational media relationsRegulatory newsInner ear biology workshopPreclinical scientistSudden sensorineural hearing lossPoster sessionsCisplatin induced ototoxicityCochlear limitedInvestor relations communicationJessica hodgson

Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022

Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the

United statesFrance generalInstitut pasteurMary jane elliott jessica hodgsonCatherine leveauOtmane boussifSensorion preclinical developmentPanel discussionInternational media relationsConsilium strategic communicationsRegulatory newsPreclinical development directorGene therapyGene therapy neurological disorders europeLaurent desireChief technical officer

Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium an

MONTPELLIER, France (BUSINESS WIRE) Regulatory News:Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation of member.

United statesFrance generalInstitut pasteurMary jane elliott jessica hodgsonCatherine leveauOtmane boussifSensorion preclinical developmentPanel discussionInternational media relationsConsilium strategic communicationsRegulatory newsPreclinical development directorGene therapyGene therapy neurological disorders europeLaurent desireGene therapy neurological disorders

Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Australian approval follows recent trial approval by regulatory authorities in France Regulatory News: Sensorion (FR0012596468 ALSEN), a pioneering clinical-stage biotechnology company which

Institut pasteurMary jane elliott jessica hodgsonCatherine leveauStrategic communicationsCochlear ltdDrug administrationInternational media relationsChief medical officerOrphan drug designationInvestigational new drugCisplatin induced ototoxicityCochlear limitedInvestor relations communicationJessica hodgson

vimarsana © 2020. All Rights Reserved.